Telix Pharmaceuticals Ltd
Business
Telix Pharmaceuticals Ltd is a global, commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies using a theranostic approach. It offers targeted radionuclide therapies and PET/SPECT diagnostic imaging agents (including PSMA, CAIX, LAT1/LAT2 and FAP-targeting products), radio-guided surgery tools, dosimetry software and AI-enabled clinical decision support. The company operates through five operating segments—Therapeutics (Tx), Precision Medicine (Px), International, MedTech and Telix Manufacturing Solutions (TMS)—and reports results across Tx, Px and TMS. Telix distributes products and clinical supplies via an integrated global manufacturing and radiopharmacy network across the Americas, EMEA and APAC, including partnerships and a U.S. radiopharmacy network.
Summary from filing dated 2026-02-20
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-7.13M |
| Total assets | $1.16B |
| Total liabilities | $748.61M |
| Stockholders' equity | — |
| Operating cash flow | — |